MetabolicMAZDUTIDE
10MG
$130
Description
Mazdutide (also known as LY3305677 or IBI362) is a novel dual GLP-1 and glucagon receptor agonist developed for metabolic research. Unlike pure GLP-1 agonists, Mazdutide's glucagon receptor activity adds a thermogenic component that increases energy expenditure and promotes hepatic fat oxidation, complementing the appetite-suppressing effects of GLP-1 activation. This dual mechanism targets both sides of the energy balance equation: reducing caloric intake through appetite suppression and increasing caloric expenditure through enhanced fat metabolism. Mazdutide represents a next-generation approach to metabolic peptide research with its unique oxyntomodulin-like activity profile.
Potential Benefits
Research Notes
Phase 2 and Phase 3 clinical trials conducted primarily in China have demonstrated significant weight reduction and metabolic improvements with Mazdutide. Published data show dose-dependent weight loss of up to 14-18% over treatment periods, along with improvements in glycemic control, liver fat content, and lipid markers. The compound's dual agonist profile, activating both GLP-1 and glucagon receptors, provides a differentiated mechanism compared to pure GLP-1 agonists like semaglutide. CAS number: 2259884-03-0.
Usage Information
For research and educational purposes only. Consult with a qualified professional before use.
All peptides must be refrigerated upon receipt.
RESEARCH PURPOSES ONLY
This product is intended for research and educational purposes only. Not intended for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.